292 related articles for article (PubMed ID: 7264298)
1. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
Balkarowa-Ständer J; Rother U; Rauterberg EW
J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
[TBL] [Abstract][Full Text] [Related]
2. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
3. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
4. Determination of the number of lytic sites in biconcave and spheroid erythrocyte ghosts after complement lysis.
Bauer J; Podack ER; Valet G
J Immunol; 1979 May; 122(5):2032-6. PubMed ID: 448115
[No Abstract] [Full Text] [Related]
5. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
6. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
Yamamoto KI
J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
[TBL] [Abstract][Full Text] [Related]
7. Restriction of complement-mediated membrane damage by the eighth component of complement: a dual role for C8 in the complement attack sequence.
Nemerow GR; Yamamoto KI; Lint TF
J Immunol; 1979 Sep; 123(3):1245-52. PubMed ID: 469249
[No Abstract] [Full Text] [Related]
8. Complement-induced ultrastructural membrane lesions: requirement for terminal components.
Packman CH; Rosenfeld SI; Weed RI; Leddy JP
J Immunol; 1976 Nov; 117(5 Pt.2):1883-9. PubMed ID: 993584
[TBL] [Abstract][Full Text] [Related]
9. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
[TBL] [Abstract][Full Text] [Related]
10. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
11. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
12. The structural events associated with the attachment of complement components to cell membranes in reactive lysis.
Dourmashkin RR
Immunology; 1978 Aug; 35(2):205-12. PubMed ID: 750370
[TBL] [Abstract][Full Text] [Related]
13. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
Lint TF; Behrends CL; Baker PJ; Gewurz H
J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
[TBL] [Abstract][Full Text] [Related]
14. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
Stewart JL; Kolb WP; Sodetz JM
J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
[TBL] [Abstract][Full Text] [Related]
15. Homologous species restriction in lysis of erythrocytes by terminal complement proteins.
Hänsch GM; Hammer CH; Vanguri P; Shin ML
Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5118-21. PubMed ID: 6946459
[TBL] [Abstract][Full Text] [Related]
16. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
[TBL] [Abstract][Full Text] [Related]
17. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
Hetland G; Bungum L
APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
[TBL] [Abstract][Full Text] [Related]
18. Deviated lysis: Transfer of complement lytic activity to unsensitized cells II. Generation of the activity by inulin and by antigen antibody complexes.
Rother U; Hänsch G; Rother K
Z Immunitatsforsch Immunobiol; 1976 Aug; 151(1):442-54. PubMed ID: 785847
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
Kitamura H; Tsuboi M
Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
[TBL] [Abstract][Full Text] [Related]
20. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
